Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: A double-blind, randomized, placebo-controlled trial

Judit Villar-García, Juan J. Hernàndez, Robert Güerri-Fernàndez, Alicia Gonzàlez, Elisabet Lerma, Ana Guelar, David Saenz, Lluisa Sorlí, Milagro Montero, Juan P. Horcajada, Hernando Knobel Freud

Research output: Contribution to journalArticleResearchpeer-review

75 Citations (Scopus)

Abstract

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. Background: Microbial translocation has been associated with an increase in immune activation and inflammation in HIV infection despite effective highly active antiretroviral therapy. It has been shown that some probiotics have a beneficial effect by reducing intestinal permeability and, consequently, microbial translocation. Objectives: To assess changes in microbial translocation and inflammation after treatment with probiotics (Saccharomyces boulardii) in HIV-1-infected patients with virologic suppression. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 44 nonconsecutive HIV-1-infected patients with viral load of <20 copies per milliliter for at least 2 years. Patients were randomized to oral supplementation with probiotics or placebo during 12 weeks. Markers of microbial translocation (lipopolysaccharide-binding protein [LBP] and soluble CD14), inflammation (interleukin 6 [IL-6], tumor necrosis factor alpha, interferon gamma, high-sensitivity C-reactive protein), and immunological and clinical data were determined before and after the intervention and 3 months after treatment discontinuation. Quantitative variables were compared using the Mann-Whitney U test, and categorical variables were compared using the Fisher exact test. Results: After 12 weeks of treatment, differences between the probiotic arm and the placebo arm were observed in LBP values (-0.30 vs +0.70 pg/mL) and IL-6 (-0.60 vs +0.78 pg/mL). These differences were also noted at 3 months after treatment withdrawal. Qualitative analysis was performed, defining a variable as "decreased" or "increased" from baseline LBP. A significant decrease of LBP at 12 weeks of treatment was observed (57.9% patients in the probiotic group vs 6.2% in the placebo group, P 0.002). Conclusions: Treatment with S. boulardii decreases microbial translocation (LBP) and inflammation parameters (IL-6) in HIV-1-infected patients with long-term virologic suppression.
Original languageEnglish
Pages (from-to)256-263
JournalJournal of Acquired Immune Deficiency Syndromes
Volume68
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • HIV infection
  • Saccharomyces boulardii
  • inflammation
  • lipopolysaccharide-binding protein
  • microbial translocation
  • probiotics

Fingerprint Dive into the research topics of 'Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: A double-blind, randomized, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Villar-García, J., Hernàndez, J. J., Güerri-Fernàndez, R., Gonzàlez, A., Lerma, E., Guelar, A., Saenz, D., Sorlí, L., Montero, M., Horcajada, J. P., & Freud, H. K. (2015). Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: A double-blind, randomized, placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes, 68, 256-263. https://doi.org/10.1097/QAI.0000000000000468